近130亿元！碧迪这项业务卖了！

IVD体外诊断网02-10

来源：CACLP2026年2月9日，沃特世正式完成与碧迪医疗旗下生物科学与诊断解决方案业务的合并，18.8亿美元的合并交易成交。早在2025年7月就已官宣该消息。BD股东持有合并后公司39.2%股份。交易后Waters强化了在流式细胞术、分子诊断等领域的布局，但收购标的业绩在2025Q4遭遇中美市场双重压力，引发股价短期波动。合并完成后，Waters将公司重组为四大业务部门：分析科学部：由前...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610442436?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-10 15:21","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610442436","market":"us","top_or_hot":-1,"title":"近130亿元！碧迪这项业务卖了！","media":"IVD体外诊断网","content":"<div>\n<p>来源：CACLP2026年2月9日，沃特世正式完成与碧迪医疗旗下生物科学与诊断解决方案业务的合并，18.8亿美元的合并交易成交。早在2025年7月就已官宣该消息。BD股东持有合并后公司39.2%股份。交易后Waters强化了在流式细胞术、分子诊断等领域的布局，但收购标的业绩在2025Q4遭遇中美市场双重压力，引发股价短期波动。合并完成后，Waters将公司重组为四大业务部门：分析科学部：由前...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016140295408f12&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>近130亿元！碧迪这项业务卖了！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n近130亿元！碧迪这项业务卖了！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 15:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016140295408f12&s=b><strong>IVD体外诊断网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>来源：CACLP2026年2月9日，沃特世正式完成与碧迪医疗旗下生物科学与诊断解决方案业务的合并，18.8亿美元的合并交易成交。早在2025年7月就已官宣该消息。BD股东持有合并后公司39.2%股份。交易后Waters强化了在流式细胞术、分子诊断等领域的布局，但收购标的业绩在2025Q4遭遇中美市场双重压力，引发股价短期波动。合并完成后，Waters将公司重组为四大业务部门：分析科学部：由前...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016140295408f12&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1894683348.USD","symbol_name":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016140295408f12&s=b","article_id":"2610442436","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021016140295408f12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610442436","pubTimestamp":1770708111,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"来源：CACLP2026年2月9日，沃特世正式完成与碧迪医疗旗下生物科学与诊断解决方案业务的合并，18.8亿美元的合并交易成交。BD股东持有合并后公司39.2%股份。管理层表示，将在整合初期重点推进BD业务与现有业务协同，并充分利用仪器更换、电子商务和服务附加等潜在增长机会。消息公布后，Waters股价在纽约证券交易所下跌12%，收于335.86美元。碧迪医疗几乎在每个国家/地区都有业务，并与世界各地的组织合作，以解决一些最具挑战性的全球健康问题。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4588":"碎股","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","BDX":"碧迪医疗","BK4504":"桥水持仓","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD"},"translate_title":"Nearly 13 billion yuan! Bidi's business is sold!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":0.9},"content_text":"来源：CACLP2026年2月9日，沃特世正式完成与碧迪医疗旗下生物科学与诊断解决方案业务的合并，18.8亿美元的合并交易成交。早在2025年7月就已官宣该消息。BD股东持有合并后公司39.2%股份。交易后Waters强化了在流式细胞术、分子诊断等领域的布局，但收购标的业绩在2025Q4遭遇中美市场双重压力，引发股价短期波动。合并完成后，Waters将公司重组为四大业务部门：分析科学部：由前Waters高级副总裁Rob Carpio领导，涵盖液相色谱、质谱、光散射与颗粒分析、Empower信息平台，以及化学耗材和服务团队；生命科学部：由前BD Biosciences全球总裁Steve Conly领导，包含流式细胞仪业务；高级诊断部：由前Waters临床业务高级副总裁Jianqing Bennet领导；材料科学部：由全球研发与战略高级副总裁Dan Rush临时领导。管理层表示，将在整合初期重点推进BD业务与现有业务协同，并充分利用仪器更换、电子商务和服务附加等潜在增长机会。公司预计2026年第一季度总营收为12亿至12.1亿美元，其中收购业务贡献约4.8亿美元；全年总营收预计为64.1亿至64.6亿美元，收购业务贡献约30亿美元，调整后EPS预计14.30至14.50美元，有机收入同比增长预计在5.5%至7%之间。消息公布后，Waters股价在纽约证券交易所下跌12%，收于335.86美元。管理层强调，尽管短期内收购业务面临压力，但长期将提升公司在生命科学和诊断领域的市场竞争力和增长潜力。碧迪医疗是世界上最大的全球医疗技术公司之一，通过改进医学发现、诊断和护理服务，推动世界健康发展。该公司通过开发创新技术、服务和解决方案来支持医疗保健前线的英雄，帮助推进患者的临床治疗和医疗保健提供者的临床流程。BD 及其 70,000 多名员工满怀热情并致力于帮助提高临床医生护理交付过程的安全性和效率，使实验室科学家能够准确检测疾病，并提高研究人员开发下一代诊断和疗法的能力。碧迪医疗几乎在每个国家/地区都有业务，并与世界各地的组织合作，以解决一些最具挑战性的全球健康问题。通过与客户密切合作，碧迪医疗可以帮助改善结果、降低成本、提高效率、提高安全性并扩大获得医疗保健的机会。声明：本微信注明来源的稿件均为转载，仅用于分享，不代表平台立场，如涉及版权等问题，请尽快联系我们，我们第一时间更正，谢谢！","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610442436","isCrawlerRequest":true}